{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:32:27Z","timestamp":1792798347100,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03361-x","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:59:35Z","timestamp":1758524375000},"page":"5708-5726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Outcomes in Patients with COPD Initiating Budesonide\/Glycopyrronium\/Formoterol Fumarate Dehydrate in Spain: ORESTES Study"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct06321731","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-9366","authenticated-orcid":false,"given":"Bernardino","family":"Alc\u00e1zar-Navarrete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-1172","authenticated-orcid":false,"given":"Juan Marco","family":"Figueira-Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0260-360X","authenticated-orcid":false,"given":"Carmen","family":"Corregidor-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-5249","authenticated-orcid":false,"given":"Eunice","family":"Fitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-3669","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"S\u00e1nchez-Covisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ORESTES group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"M\u00e1rquez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Velasco-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mart\u00edn-Lana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Mar\u00eda","family":"Garc\u00eda-Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Fuster-Gomila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gonz\u00e1lez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Bruguera-Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Pascual-Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galo David","family":"Granados-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagore","family":"Blanco-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Pallar\u00e9s-Sanmart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Casitas-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Galera-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Mar\u00eda","family":"Gotera-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Margallo-Iribarnegaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bernabeu-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Murga-Arizabaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Saura-Vinuesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Herrej\u00f3n-Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Khadour-Khadour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"11","key":"3361_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","volume":"206","author":"B Celli","year":"2022","unstructured":"Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206(11):1317\u201325.","journal-title":"Am J Respir Crit Care Med"},{"key":"3361_CR2","unstructured":"Chronic obstructive pulmonary disease (COPD). World Health Organization: World Health Organization; 2024 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd)."},{"key":"3361_CR3","unstructured":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2025 report). Global Initiative for Chronic Obstructive Lung Disease 2025."},{"issue":"1","key":"3361_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.arbr.2020.07.017","volume":"57","author":"JB Soriano","year":"2021","unstructured":"Soriano JB, Alfageme I, Miravitlles M, de Lucas P, Soler-Catalu\u00f1a JJ, Garc\u00eda-R\u00edo F, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Archivos de Bronconeumolog\u00eda (English Edition). 2021;57(1):61\u20139.","journal-title":"Archivos de Bronconeumolog\u00eda (English Edition)"},{"issue":"1","key":"3361_CR5","doi-asserted-by":"publisher","first-page":"21154","DOI":"10.1038\/s41598-022-24719-z","volume":"12","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Ortiz A, Tyrovolas S, Fern\u00e1ndez E, Guy D, White TM, et al. A GBD 2019 study of health and sustainable development goal gains and forecasts to 2030 in Spain. Sci Rep. 2022;12(1):21154.","journal-title":"Sci Rep"},{"issue":"10342","key":"3361_CR6","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227\u201342.","journal-title":"Lancet"},{"key":"3361_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/COPD.S36997","volume":"7","author":"MK Pasquale","year":"2012","unstructured":"Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757\u201364.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"3361_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/thx.2005.049940","volume":"61","author":"LC Price","year":"2006","unstructured":"Price LC, Lowe D, Hosker HS, Anstey K, Pearson MG, Roberts CM, et al. UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax. 2006;61(10):837\u201342.","journal-title":"Thorax"},{"issue":"12","key":"3361_CR9","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128\u201338.","journal-title":"N Engl J Med"},{"issue":"5 Pt 1","key":"3361_CR10","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","volume":"157","author":"TA Seemungal","year":"1998","unstructured":"Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418\u201322.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"3361_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847\u201352.","journal-title":"Thorax"},{"key":"3361_CR12","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/COPD.S139470","volume":"12","author":"DM Halpin","year":"2017","unstructured":"Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017;12:2891\u2013908.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"3361_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.chest.2023.08.014","volume":"164","author":"J Bourbeau","year":"2023","unstructured":"Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne MF, Kermelly SB, et al. 2023 Canadian Thoracic Society Guideline on pharmacotherapy in patients with stable COPD. Chest. 2023;164(5):1159\u201383.","journal-title":"Chest"},{"issue":"1","key":"3361_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","volume":"58","author":"M Miravitlles","year":"2022","unstructured":"Miravitlles M, Calle M, Molina J, Almagro P, G\u00f3mez JT, Trigueros JA, et al. Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69\u201381.","journal-title":"Arch Bronconeumol"},{"key":"3361_CR15","unstructured":"Trixeo Aerosphere: Summary of Product Characteristics. European Medicines Agency; 2024."},{"issue":"5","key":"3361_CR16","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","volume":"162","author":"B Alc\u00e1zar-Navarrete","year":"2022","unstructured":"Alc\u00e1zar-Navarrete B, Jamart L, S\u00e1nchez-Covisa J, Ju\u00e1rez M, Graefenhain R, Sicras-Mainar A. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022;162(5):1017\u201329.","journal-title":"Chest"},{"issue":"10","key":"3361_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"3361_CR18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. Fulfil trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438\u201346.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3361_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"18","key":"3361_CR20","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"issue":"5","key":"3361_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553\u201364.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10125","key":"3361_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076\u201384.","journal-title":"Lancet"},{"issue":"10048","key":"3361_CR23","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, Pavli\u0161ov\u00e1 I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963\u201373.","journal-title":"Lancet"},{"key":"3361_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106509","volume":"185","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Trivedi R, Jenkins M, et al. Benefits of budesonide\/glycopyrrolate\/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021;185:106509.","journal-title":"Respir Med"},{"key":"3361_CR25","doi-asserted-by":"publisher","first-page":"175346662110343","DOI":"10.1177\/17534666211034329","volume":"15","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Martinez FJ, Singh D, Trivedi R, Jenkins M, Darken P, et al. Improvements in lung function with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis. 2021;15:17534666211034328.","journal-title":"Ther Adv Respir Dis"},{"key":"3361_CR26","doi-asserted-by":"crossref","unstructured":"Hammadi A, Hoyas-S\u00e1nchez C, Romero-Linares A, \u00c1lvarez-Muro L, Men\u00e9ndez-Lobo A, Romeral-Navarro D, et al. All-cause and cardiovascular mortality with single inhaler triple therapy versus double therapies for COPD: a systematic review and metanalysis. Arch Bronconeumol. 2025.","DOI":"10.1016\/j.arbres.2025.02.004"},{"issue":"1","key":"3361_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12890-019-0882-y","volume":"19","author":"L Pahus","year":"2019","unstructured":"Pahus L, Burgel PR, Roche N, Paillasseur JL, Chanez P. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm Med. 2019;19(1):127.","journal-title":"BMC Pulm Med"},{"key":"3361_CR28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/COPD.S452624","volume":"19","author":"H M\u00fcllerov\u00e1","year":"2024","unstructured":"M\u00fcllerov\u00e1 H, Chan JSK, Heatley H, Carter V, Townend J, Skinner D, et al. Budesonide\/glycopyrrolate\/formoterol for the management of COPD in a UK primary care population: real-world use and early medication success. Int J Chron Obstruct Pulmon Dis. 2024;19:1153\u201366.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3361_CR29","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2147\/COPD.S432963","volume":"18","author":"C Strange","year":"2023","unstructured":"Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, et al. Exacerbations and real-world outcomes after single-inhaler triple therapy of budesonide\/glycopyrrolate\/formoterol fumarate, among patients with COPD: results from the EROS (US) Study. Int J Chron Obstruct Pulmon Dis. 2023;18:2245\u201356.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3361_CR30","doi-asserted-by":"crossref","unstructured":"Sun Y, Chen Y, Zhang X, Guo R, Zhou L, Feng J, et al. Real-world safety of budesonide\/glycopyrrolate\/formoterol in Chinese patients with chronic obstructive pulmonary disease. Eur Respir J 64(suppl 68):PA2999.","DOI":"10.1183\/13993003.congress-2024.PA2999"},{"issue":"4","key":"3361_CR31","doi-asserted-by":"publisher","first-page":"A4716","DOI":"10.1016\/j.chest.2024.06.2841","volume":"166","author":"Y Sun","year":"2024","unstructured":"Sun Y, Chen Y, Zhang X, Guo R, Zhou L, Feng J, et al. Effectiveness of budesonide\/glycopyrrolate\/formoterol fumarate in Chinese patients with chronic obstructive pulmonary disease in real-world clinical practice. Chest. 2024;166(4):A4716\u20137.","journal-title":"Chest"},{"issue":"4","key":"3361_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semerg.2024.102418","volume":"51","author":"A Calder\u00f3n-Montero","year":"2025","unstructured":"Calder\u00f3n-Montero A, de Miguel Diez J, de Sim\u00f3n Guti\u00e9rrez R, Campos T\u00e9llez S, Chac\u00f3n Moreno AD, Alonso Avil\u00e9s R, et al. Triple inhaled therapy of formoterol\/glycopyrrolate\/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions. Medicina de Familia SEMERGEN. 2025;51(4):102418.","journal-title":"Medicina de Familia SEMERGEN"},{"key":"3361_CR33","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2147\/COPD.S338436","volume":"17","author":"KJ Rothnie","year":"2022","unstructured":"Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS. Characteristics of new users of single- and multiple-inhaler triple therapy for COPD in primary care in England. Int J Chron Obstruct Pulmon Dis. 2022;17:1455\u201366.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3361_CR34","doi-asserted-by":"publisher","first-page":"175346662311645","DOI":"10.1177\/17534666231164534","volume":"17","author":"EC Portillo","year":"2023","unstructured":"Portillo EC, Pollack M, Lee I, Sun K, Zhao X, Kruse L, et al. Characteristics of initiators of budesonide\/glycopyrrolate\/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study. Ther Adv Respir Dis. 2023;17:17534666231164534.","journal-title":"Ther Adv Respir Dis"},{"issue":"11","key":"3361_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.arbres.2023.07.015","volume":"59","author":"M Calle Rubio","year":"2023","unstructured":"Calle Rubio M, Miravitlles M, L\u00f3pez-Campos JL, Alc\u00e1zar Navarrete B, Soler Catalu\u00f1a JJ, Fuentes Ferrer ME, et al. Inhaled maintenance therapy in the follow-up of COPD in outpatient respiratory clinics. Factors related to inhaled corticosteroid use. EPOCONSUL 2021 audit. Arch Bronconeumol. 2023;59(11):725\u201335.","journal-title":"Arch Bronconeumol"},{"key":"3361_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2147\/COPD.S490227","volume":"20","author":"M Calle Rubio","year":"2025","unstructured":"Calle Rubio M, Trigueros Carrero JA, Chaparro Briones P, Escudero Herrera L, Pollack M, Hern\u00e1ndez Subir\u00e1 I, et al. Characteristics of patients receiving budesonide\/glycopyrronium\/formoterol for chronic obstructive pulmonary disease in Spain: The AURA Study. Int J Chron Obstruct Pulmon Dis. 2025;20:999\u20131008.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"3361_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","volume":"3","author":"W Chen","year":"2015","unstructured":"Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631\u20139.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3361_CR38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1378\/chest.12-0938","volume":"143","author":"JD Maclay","year":"2013","unstructured":"Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143(3):798\u2013807.","journal-title":"Chest"},{"issue":"2","key":"3361_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.recesp.2024.06.004","volume":"78","author":"S Santos","year":"2025","unstructured":"Santos S, Manito N, S\u00e1nchez-Covisa J, Hern\u00e1ndez I, Corregidor C, Escudero L, et al. Risk of severe cardiovascular events following COPD exacerbations: results from the EXACOS-CV study in Spain. Rev Esp Cardiol (Engl Ed). 2025;78(2):138\u201350.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"3361_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12890-025-03823-6","volume":"25","author":"Y Li","year":"2025","unstructured":"Li Y, Li J, Yang H, Zhang Y. Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2025;25(1):345.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"3361_CR41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","volume":"107","author":"MJ M\u00e4kel\u00e4","year":"2013","unstructured":"M\u00e4kel\u00e4 MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481\u201390.","journal-title":"Respir Med"},{"key":"3361_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/COPD.S347735","volume":"17","author":"J Tkacz","year":"2022","unstructured":"Tkacz J, Evans KA, Touchette DR, Portillo E, Strange C, Staresinic A, et al. PRIMUS - prompt initiation of maintenance therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:329\u201342.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"3361_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1164\/rccm.202312-2311OC","volume":"211","author":"D Singh","year":"2025","unstructured":"Singh D, Martinez FJ, Hurst JR, Han MK, Gale CP, Fredriksson M, et al. Effect of triple therapy on cardiovascular and severe cardiopulmonary events in chronic obstructive pulmonary disease: a post hoc analysis of a randomized, double-blind, phase 3 clinical trial (ETHOS). Am J Respir Crit Care Med. 2025;211(2):205\u201314.","journal-title":"Am J Respir Crit Care Med"},{"key":"3361_CR44","unstructured":"ClinicalTrials.gov. A study evaluating the efficacy of budesonide, glycopyrronium and formoterol fumarate metered dosed inhaler on cardiopulmonary outcomes in chronic obstructive pulmonary disease (THARROS)."},{"issue":"7","key":"3361_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0327775","volume":"20","author":"M Calle Rubio","year":"2025","unstructured":"Calle Rubio M, Alc\u00e1zar-Navarrete B, L\u00f3pez-Campos JL, Miravitlles M, Soler-Catalu\u00f1a JJ, Fuentes Ferrer ME, et al. Characteristics and actions in high-risk COPD in unstable patients: the EPOCONSUL audit. PLoS One. 2025;20(7):e0327775.","journal-title":"PLoS One"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03361-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:23:41Z","timestamp":1769498621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03361-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3361"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03361-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bernardino Alc\u00e1zar-Navarrete declares conflicts of interest for having received consulting fees, research grants, or lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, GSK, Laboratorios Bial, Laboratorios Menarini, and Sanofi. Juan Marco Figueira-Gon\u00e7alves has received honoraria for speaking engagements and funding for conference attendance from AstraZeneca, Laboratories Esteve, MundiPharma, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GSK, Chiesi, Novartis, and Gebro Pharma. Carmen Corregidor-Garc\u00eda, Eunice Fitas, and Joaqu\u00edn S\u00e1nchez-Covisa are employees of AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"The present study was approved by the Ethics Committee of Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife) in Spain during the meeting held on the 25\n                      th\n                      of May 2024. The study was in accordance with ethical principles that are consistent with the Declaration of Helsinki (1964 and its later amendments), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice, and the applicable legislation on non-interventional studies and\/or observational studies. Given the retrospective and non-interventional nature of the study and according to the current local regulations, the Ethics Committee endorsed a waiver for written informed consent from patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}